Pharmacokinetics of ropivacaine in patients with chronic end-stage liver disease

Anesthesiology

Volumn 106, Issue 1, 2007, Pages 43-55

  Jokinen, Mika J ^a,f   Neuvonen, Pertti J ^a   Lindgren, Leena ^b   Höckerstedt, Krister ^a   Sjövall, Jan ^c,d   Breuer, Olof ^d   Askemark, Yvonne ^d   Ahonen, Jouni ^a   Olkkola, Klaus T ^e  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITY OF TURKU   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

2',6' PIPECOLOXYLIDIDE; 3 HYDROXYROPIVACAINE; ALBUMIN; DRUG METABOLITE; PREALBUMIN; ROPIVACAINE; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INFUSION; DRUG URINE LEVEL; FEMALE; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; MALE; PATIENT MONITORING; PLASMA CLEARANCE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE; THROMBOPLASTIN TIME; VOLUNTEER;

ADULT; AMIDES; ANESTHETICS, LOCAL; CHOLANGITIS, SCLEROSING; CHRONIC DISEASE; CYTOCHROME P-450 CYP1A2; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, BILIARY; LIVER DISEASES, ALCOHOLIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED;

EID: 33845951574     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/00000542-200701000-00011     Document Type: Article

References (37)

1. McClure JH: Ropivacaine. Br J Anaesth 1996; 76:300-7
2. Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, Widman M: Metabolism and excretion of ropivacaine in humans. Drug Metab Dispos 1996; 24:962-8
3. Oda Y, Furuichi K, Tanaka K, Hiroi T, Imaoka S, Asada A, Fujimori M, Funae Y: Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450. ANESTHESIOLOGY 1995; 82:214-20
4. Ekstrom G, Gunnarsson UB: Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Drug Metab Dispos 1996; 24:955-61
5. Arlander E, Ekstrom G, Alm C, Carrillo JA, Bielenstein M, Bottiger Y, Bertilsson L, Gustafsson LL: Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther 1998; 64:484-91
6. Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT: The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine. Anesth Analg 2000; 91:1207-12
7. Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ: Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. Clin Pharmacol Ther 2001; 70:344-50
8. Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT: Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. Pharmacol Toxicol 2001; 88:187-91
9. Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ: Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. Eur J Clin Pharmacol 2003; 58:653-7
10. Burm AG, Stienstra R, Brouwer RP, Emanuelsson BM, van Kleef JW: Epidural infusion of ropivacaine for postoperative analgesia after major orthopedic surgery: Pharmacokinetic evaluation. ANESTHESIOLOGY 2000; 93:395-403
11. Hayes PC: Liver disease and drug disposition. Br J Anaesth 1992; 68:459-61
12. Tucker GT: Pharmacokinetics of local anaesthetics. Br J Anaesth 1986; 58:717-31
13. Thomas JM, Schug SA: Recent advances in the pharmacokinetics of local anaesthetics: Long-acting amide enantiomers and continuous infusions. Clin Pharmacokinet 1999; 36:67-83
14. Tucker GT: Safety in numbers: The role of pharmacokinetics in local anesthetic toxicity. The 1993 ASRA Lecture. Reg Anesth 1994; 19:155-63
15. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-23
16. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-9
17. Engman M, Neidenstrom P, Norsten-Hoog C, Wiklund SJ, Bondesson U, Arvidsson T: Determination of ropivacaine and [2H3]ropivacaine in biological samples by gas chromatography with nitrogen-phosphorus detection or mass spectrometry. J Chromatogr B Biomed Sci Appl 1998; 709:57-67
18. Abdel-Rehim M, Bielenstein M, Askemark Y: Determination of ropivacaine and its metabolites in patient urine: Advantage of liquid chromatography-tandem mass spectrometry over liquid chromatography-UV detection and liquid chromatography-mass spectrometry. Analytica Chimica Acta 2003; 492:253-60
19. Arvidsson T, Askemark Y, Halldin MM: Liquid chromatographic bioanalytical determination of ropivacaine, bupivacaine and major metabolites. Biomed Chromatogr 1999; 13:286-92
20. Ekatodramis G, Borgeat A, Huledal G, Jeppsson L, Westman L, Sjovall J: Continuous interscalene analgesia with ropivacaine 2 mg/ml after major shoulder surgery. ANESTHESIOLOGY 2003; 98:143-50
21. Magorian T, Wood P, Caldwell J, Fisher D, Segredo V, Szenohradszky J, Sharma M, Gruenke L, Miller R: The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg 1995; 80:754-9
22. Servin FS, Lavaut E, Kleef U, Desmonts JM: Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane: A clinical and pharmacokinetic study. ANESTHESIOLOGY 1996; 84:1092-100
23. Fuller R, Hoppel C, Ingalls ST: Furosemide kinetics in patients with hepatic cirrhosis with ascites. Clin Pharmacol Ther 1981; 30:461-7
24. Servin F, Cockshott ID, Farinotti R, Haberer JP, Winckler C, Desmonts JM: Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth 1990; 65:177-83
25. Knudsen K, Beckman Suurkula M, Blomberg S, Sjovall J, Edvardsson N: Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth 1997; 78:507-14
26. Emanuelsson BM, Zaric D, Nydahl PA, Axelsson KH: Pharmacokinetics of ropivacaine and bupivacaine during 21 hours of continuous epidural infusion in healthy male volunteers. Anesth Analg 1995; 81:1163-8
27. Erichsen CJ, Sjövall J, Kehlet H, Hedlund C, Arvidsson T: Pharmacokinetics and analgesic effect of ropivacaine during continuous epidural infusion for postoperative pain relief. ANESTHESIOLOGY 1996; 84:834-42
28. Emanuelsson BM, Persson J, Alm C, Heller A, Gustafsson LL: Systemic absorption and block after epidural injection of ropivacaine in healthy volunteers. ANESTHESIOLOGY 1997; 87:1309-17
29. Bergquist C, Lindegård J, Salmonson T: Dosing recommendations in liver disease. Clin Pharmacol Ther 1999; 66:201-4
30. Moller S, Henriksen JH: Cirrhotic cardiomyopathy: A pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87:9-15
31. Maroto A, Gines P, Arroyo V, Gines A, Salo J, Claria J, Jimenez W, Bru C, Rivera F, Rodes J: Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction. Hepatology 1993; 17:788-93
32. Hu OY, Tang HS, Chang CL: Novel galactose single point method as a measure of residual liver function: Example of cefoperazone kinetics in patients with liver cirrhosis. J Clin Pharmacol 1995; 35:250-8
33. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-23
34. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M: Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61:331-9
35. Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P: Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: Effects of liver function. Clin Pharmacol Ther 2004; 75:80-8
36. Gantenbein M, Attolini L, Bruguerolle B, Villard P-H, Puyoou F, Durand A, Lacarelle B, Hardwigsen J, Le-Treut Y-P: Oxidative metabolism of bupivacaine into pipecolylxylidine in humans in mainly catalyzed by CYP3 A. Drug Metab Dispos 1999; 28:383-5
37. Lee JH, Jung WJ, Choi KH, Chun MH, Ha SB, Lee SK: Nerve conduction study on patients with severe liver syndrome and its change after transplantation. Clin Transplant 2002; 16:430-2